Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Clicks: 337
ID: 274192
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Reference Key
m2020theautologous Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cavo M;Gay F;Beksac M;Pantani L;Petrucci MT;Dimopoulos MA;Dozza L;van der Holt B;Zweegman S;Oliva S;van der Velden VHJ;Zamagni E;Palumbo GA;Patriarca F;Montefusco V;Galli M;Maisnar V;Gamberi B;Hansson M;Belotti A;Pour L;Ypma P;Grasso M;Croockewit A;Ballanti S;Offidani M;Vincelli ID;Zambello R;Liberati AM;Andersen NF;Broijl A;Troia R;Pascarella A;Benevolo G;Levin MD;Bos G;Ludwig H;Aquino S;Morelli AM;Wu KL;Boersma R;Hajek R;Durian M;von dem Borne PA;Caravita di Toritto T;Zander T;Driessen C;Specchia G;Waage A;Gimsing P;Mellqvist UH;van Marwijk Kooy M;Minnema M;Mandigers C;Cafro AM;Palmas A;Carvalho S;Spencer A;Boccadoro M;Sonneveld P;;
Journal The Lancet. Haematology
Year 2020
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.